This beaten stock may double over the next 5 years
CRISPR shares have lost speed in recent years. The company’s lone market product does not yet generate much revenue. This needs to change over time and biotechnology may mark additional clinical victories. 10 shares we like better than CRISPR therapies › Although it has made significant clinical progress, CRISPR therapeutics (Nasdaq: Crsp) It has been … Read more